Recombinant Human Serum Albumin(OsrHSA) Derived From Oryza Sativa Has Been Approved By CFDA For The Clinical Trial In China   OsrHSA, a recombinant human serum albumin derived from transgenic rice seeds has gained the approval of the clinical trial from Chinese Food and Drug Administration (CFDA) at 28 April, 2017. It is a milestone event in the research and applications of plant bioreactor, which ... Posted by Site editor|2017-05-22 LearnMore
Healthgen Biotech's tenth anniversary celebration   In 18th Dec 2016, the innovative high-tech enterprise- Wuhan Healthgen Biotechnology Corp.(Healthgen Biotech, Securities Code: 833101) which is focusing on developing, manufacturing and marketing a serious of recombinant proteins and small peptide products in the rice g... Posted by Site editor|2016-12-24 LearnMore
PLOS ONE: Immunotoxicity Assessment of Rice-Derived Recombinant Human Serum Albumin Using Human Peripheral Blood Mononuclear Cells A research team led by Prof. Daichang Yang, from College of Life Sciences, Wuhan University, and Wuhan Healthgen Biotechnology Co., Ltd. started the research and development of using plant-derived therapeutic proteins to replace the plasma-derived ones since 2006, has achieved a ... Posted by Site editor|2014-08-14 LearnMore
Healthgen Biotech attended the Vaccine World Summit India 2014   Wuhan Healthgen Biotechnology Corp.(Healthgen Biotech) attended the Vaccine World Summit India 2014 at Hyderabad International Convention Centre, India in 4-6 March. Our booth was located in Hall 2.     The Vaccine World Summit is the most sought ... Posted by Site editor|2014-03-12 LearnMore
Pre 1 2 3 4 5 Next

Wuhan Healthgen Biotechnology Corp.

Tel. +86 027 59301891 Ext 8015

Fax. +86 027 59403931

E-mail cjing@oryzogen.com

268 Shendun 5th Road, East Lake High-Tech Development Zone, Wuhan, China 430020

Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3